[SH:1][C:2]1[N:7]=[CH:6][CH:5]=[CH:4][N:3]=1.[H-].[Na+].F[C:11]1[C:12]([CH:25]=[O:26])=[CH:13][C:14]2[C:15]([CH3:24])([CH3:23])[CH2:16][CH2:17][C:18]([CH3:22])([CH3:21])[C:19]=2[CH:20]=1>CN(C)C=O>[CH3:21][C:18]1([CH3:22])[CH2:17][CH2:16][C:15]([CH3:23])([CH3:24])[C:14]2[CH:13]=[C:12]([CH:25]=[O:26])[C:11]([S:1][C:2]3[N:7]=[CH:6][CH:5]=[CH:4][N:3]=3)=[CH:20][C:19]1=2To a solution of 0.479 g (4.27 mmol) of 2-mercaptopyrimidine in 11 mL dimethylformamide was added 0.108 g (4.27 mmol) of 95% sodium hydride. After 20 minutes, 1.00 g (4.27 mmol) of 3-fluoro-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthaldehyde was added and the resulting solution was heated at reflux. After 18 hours, the reaction mixture was cooled to room temperature and partitioned between ethyl acetate and water. The organic phase was washed with water, brine, dried over anhydrous sodium sulfate and concentrated in vacuo. The product was purified by flash chromatography on silica (15% ethyl acetate/hexane) to afford 0.219 g (16%) of 5,5,8,8-tetramethyl-3-(pyrimidin-2-yl-thio)-5,6,7,8-tetrahydro-2-naphthaldehyde (mp=143.2-145.8). Horner-Emmons olefination, followed by ester saponification gave 4-{(E)-2-[5,5,8,8-Tetramethyl-3-(mercaptopyrmidin-2-yl)-5,6,7,8-tetrahydro-naphthalen-2-yl)vinyl]benzoic acid 155 (mp=283-283.5). Substitution of 2-mercaptopyrimidine with 2-mercaptothiazole gave 4-{(E)-2-[5,5,8,8-Tetramethyl-3-(mercaptothiazol-2-yl)-5,6,7,8-tetrahydro-naphthalen-2-yl)vinyl]benzoic acid 154 (MH+=450).